Oyster Point Pharma meets primary endpoint in dry eye nasal spray study

A potential nasal spray treatment for dry eye signs and symptoms met its primary endpoint of increased Schirmer’s score in a phase 3 trial, Oyster Point Pharma announced in a press release.
The multicenter, double-masked, randomized, controlled ONSET-2 trial evaluated safety and efficacy of OC-01 (varenicline) nasal spray, a selective nicotinic acetylcholine receptor agonist, at two doses compared with vehicle in 758 patients.
Twice daily dosing of both a 0.6 mg/mL dose and a 1.2 mg/mL dose yielded statistically significant greater improvement of at least 10 mm on Schirmer’s score